500,000 Shares in Catalent, Inc. (NYSE:CTLT) Purchased by Mizuho Markets Americas LLC

Mizuho Markets Americas LLC purchased a new position in shares of Catalent, Inc. (NYSE:CTLT - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 500,000 shares of the company's stock, valued at approximately $30,285,000. Mizuho Markets Americas LLC owned 0.28% of Catalent as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in CTLT. Thurston Springer Miller Herd & Titak Inc. bought a new stake in shares of Catalent in the 2nd quarter valued at approximately $42,000. Sentry Investment Management LLC acquired a new position in shares of Catalent during the 3rd quarter worth $53,000. Longfellow Investment Management Co. LLC lifted its stake in shares of Catalent by 45.7% in the 2nd quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company's stock valued at $55,000 after purchasing an additional 305 shares during the last quarter. GAMMA Investing LLC boosted its holdings in Catalent by 25.9% in the second quarter. GAMMA Investing LLC now owns 1,032 shares of the company's stock worth $58,000 after purchasing an additional 212 shares in the last quarter. Finally, Intact Investment Management Inc. acquired a new position in Catalent during the third quarter worth $73,000.

Catalent Stock Performance

CTLT stock traded up $0.19 on Friday, reaching $59.10. 1,488,223 shares of the company were exchanged, compared to its average volume of 2,034,855. The firm has a market capitalization of $10.73 billion, a PE ratio of -26.15, a PEG ratio of 2.35 and a beta of 1.16. Catalent, Inc. has a 12 month low of $36.74 and a 12 month high of $61.20. The stock's fifty day moving average price is $59.84 and its 200 day moving average price is $58.20. The company has a debt-to-equity ratio of 1.38, a current ratio of 2.51 and a quick ratio of 1.96.

Catalent (NYSE:CTLT - Get Free Report) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by ($0.18). Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. The company had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.06 billion. During the same quarter in the previous year, the firm posted ($0.10) EPS. The business's revenue for the quarter was up 4.2% compared to the same quarter last year. On average, research analysts anticipate that Catalent, Inc. will post 0.84 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have weighed in on CTLT shares. StockNews.com raised Catalent from a "sell" rating to a "hold" rating in a research report on Thursday. Robert W. Baird reaffirmed a "neutral" rating and set a $63.50 target price on shares of Catalent in a research report on Tuesday, September 24th. William Blair reiterated a "market perform" rating on shares of Catalent in a report on Tuesday, September 3rd. Finally, Baird R W cut shares of Catalent from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, September 24th. Nine investment analysts have rated the stock with a hold rating, According to data from MarketBeat, Catalent presently has an average rating of "Hold" and an average price target of $59.83.

Insider Buying and Selling at Catalent

In other news, Director Michelle R. Ryan sold 2,800 shares of the firm's stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $59.70, for a total transaction of $167,160.00. Following the completion of the transaction, the director now directly owns 10,835 shares of the company's stock, valued at approximately $646,849.50. This trade represents a 20.54 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider David Mcerlane sold 1,994 shares of the company's stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $59.97, for a total transaction of $119,580.18. Following the completion of the sale, the insider now directly owns 36,304 shares in the company, valued at approximately $2,177,150.88. The trade was a 5.21 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 5,114 shares of company stock valued at $305,931 in the last quarter. Corporate insiders own 0.31% of the company's stock.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.